Zonisamide in the treatment of epilepsy

Bibliography

• Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia 1986;1:66-75
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;5:314-19
   Google Scholar
• Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 2001;42:(Suppl 3):31-5
   PubMedGoogle Scholar
• Deckers CL. Place of polytherapy in the early treatment of epilepsy. CNS Drugs 2002;3:155-63
   Google Scholar
• Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008;2:181-6
   Google Scholar
• Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68(Supp 2):S11-16
   PubMedGoogle Scholar
• Frampton JE, Scott LJ. Zonisamide. A review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;1:1-19
   Google Scholar
• Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998;6:593-7
   Google Scholar
• Kawai M, Hiramatsu M, Endo A, Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from hippocampal slices of E1 mice. Neurosciences 1994;20:115-19
   Google Scholar
• Zhu WJ, Rogawski MA. Zonisamide depresses excitatory synaptic transmission by a presynaptic action. Epilepsia 1999;40(Suppl 7):245
   Google Scholar
• Ueda Y, Doi T, Tokumaru J, Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;1-2:1-6
   Google Scholar
• Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-8
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawakami K, Nishimura S, Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7
   PubMed Web of Science ®Google Scholar
• Okada M, Hirano T, Kawata Y, Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999;2-3:187-97
   Google Scholar
• Okada M, Kaneko S, Hirano T, Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;3:193-205
   Google Scholar
• Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;4:416-18
   Google Scholar
• Thone J, Leniger T, Splettstosser F, Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 2008;2-3:105-11
   Google Scholar
• Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 1995;21:23-9
   Web of Science ®Google Scholar
• Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993;5:760-87
   Google Scholar
• Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004;13(Suppl 2):S41-8
   PubMedGoogle Scholar
• Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007;3:435-41
   Google Scholar
• Wagner JG, Sackellares JC, Donofrio PD, Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984;6:277-83
   PubMedGoogle Scholar
• Kochak GM, Page JG, Buchanan RA, Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998;2:166-71
   Google Scholar
• Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;8:191-9S
   Google Scholar
• Asadi-Pooya AA. Drug compliance of children and adolescents with epilepsy. Seizure 2005;6:393-5
   Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004; 13(Suppl 1):5-9
   Google Scholar
• Ragueneau-Majlessi I, Levy RH, Bergen D, Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res 2004;1:1-11
   Google Scholar
• Levy RH, Ragueneau-Majlessi I, Brodie MJ, Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patientes with epilepsy. Ther Drug Monit 2005;2:193-8
   Google Scholar
• Levy RH, Ragueneau-Majlessi I, Garnett WR. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol 2004;44:1230-4
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Brodie M, Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet 2005;5:517-23
   Google Scholar
• Odani A, Hashimoto Y, Takayanagi K, Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 1996;3:444-8
   Google Scholar
• Minami T, Ieiri I, Ohtsubo K, Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia 1994;5:1023-5
   Google Scholar
• McJilton J, De Toledo J, DeCerce J. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. Epilepsia 1996;37(Suppl 5):173
   Google Scholar
• Glauser TA, Pellock JM. Efficacy and safety of zonisamide in pediatric epilepsy: the Japananese experience. Epilepsia 2000;41(Suppl 7):190
   Google Scholar
• Yagi K. Overview of Japanese experience-controlled and uncontrolled trials. Seizure 2004;13(Suppl 2):S11-15
   PubMedGoogle Scholar
• Schmidt D, Jacob R, Loiseau P, Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;1:67-73
   Google Scholar
• Faught E, Ayala R, Montouris GG, Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;10:1774-9
   Google Scholar
• Sackellares JC, Ramsay RE, Wilder BJ, Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;6:610-17
   Google Scholar
• Brodie MJ, Duncan R, Vespignani H, Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;1:31-41
   Google Scholar
• Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005;4:CD001416
   Google Scholar
• French JA, Ruelle AD. Zonisamide reduces seizure frequency over time in long-term continuation studies. Epilepsia 2002;43:241
   Google Scholar
• Alapati A, Hall-Bell C, Faught ER. Safety and efficacy of zonisamide adjunctive therapy for refractoray complex partial seizures: an open label study. Epilepsia 2000;41(Suppl 7):225
   Google Scholar
• Brodie MJ. Zonisamide clinical trials: European experience. Seizure 2004;13(Suppl 1):66-70
   Google Scholar
• Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13(Suppl 1):59-65
   PubMed Web of Science ®Google Scholar
• Tosches W, Tisdell J. Efficacy and safety of long-term zonisamide monotherapy and adjunctive therapy [abstract p346]. Epilepsia 2005;46(Suppl 6):143
   Google Scholar
• Tosches W, Tisdell J. Long-term zonisamide therapy in geriatric patients: efficacy and safety. Epilepsia 2005;46(Suppl 7): abstract 2295
   Google Scholar
• Wroe S, Brodie MJ. Long-term efficacy and safety with zonisamide: interim analysis of an open-label study. Epilepsia 2005;46(Suppl 6):118
   Google Scholar
• Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007;4:296-304
   Google Scholar
• Ono T, Yagi K, Seino M. Clinical efficacy and safety of a new antiepileptic drug, zonisamide. A multi-institutional phase three study. Clin Psychiatry 1988;30:471-82
   Google Scholar
• Leppik I, Willmore L, Homan R, Efficacy and safety of zonisamide in pediatric patientes with epilepsy. Epilepsy Res 1993;14:165-73
   PubMed Web of Science ®Google Scholar
• Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies – our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;1:79-85
   Google Scholar
• Saleh FG, Mousli H, Bruno J, Zonisamide efficacy as adjunctive therapy in adults with intractable seizures. Epilepsia 2003;44(Suppl 9):262
   Google Scholar
• Schacht H, Gates J, Ankenbauer J, Tolerability of rapid zonisamide (ZNS) titration in hospital setting [abstract 2250]. Epilepsia 2002;43(Suppl 7):199
   PubMedGoogle Scholar
• Wellmer S, Wellmer J, Bauer J. Zonisamid zur Komedikation fokaler Epilepsien. Nervenarzt 2008;79:1416-23
   PubMedGoogle Scholar
• Marmarou A, Pellock JM. Zonisamide: physician and patient experiences. Epilepsy Res 2005:63-9
   PubMedGoogle Scholar
• Bös M, Bauer J. Antikonvulsive Komedikation von Topiramat und Zonisamid. Nervenarzt 2007;78:1425-9
   PubMedGoogle Scholar
• Newmark ME, Dubinsky S. Zonisamide monotherapy in a multi-group clinic. Seizure 2004;4:223-5
   Google Scholar
• Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;3:522-6
   Google Scholar
• Seino M, Ohkuma T, Miyasaka M. Efficacy evaluation of AD-810 (zonisamide), results of a double blind comparison with carbamazepine (CBZ). J Clin Exp Med 1988;144:275-91
   Google Scholar
• Oguni H, Hayashi K, Fukuyama Y, Phase III study of a new antiepileptic AD-810, zonisamide in childhood epilepsy [Japanese]. Jpn J Pediatr 1988;41:439-50
   Google Scholar
• Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13(Suppl 2):S26-32
   PubMedGoogle Scholar
• Park SP, Kim SY, Hwang YH, Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;4:175-80
   Google Scholar
• Andriola M, Vitale SJ, Firas B, Zonisamide as adjunctive and monotherapy in absence epilepsy. Epilepsia 2002;43:190
   Google Scholar
• Hershkowitz L. Zonisamide therapy in patients with absence seizures. Epilepsia 2002;43:193
   PubMedGoogle Scholar
• Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;1-2:31-4
   Google Scholar
• Biton V, Bebin ME. Multicenter, open-label assessment of the efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2002;43(Suppl 7):190
   Google Scholar
• Thomas G, McCabe P. Clinical use of zonisamide in generalized seizure disorders. Epilepsia 2005;46(Suppl 7): abatract 2294
   Google Scholar
• Conry JA, Ramsay RE, Vossler D, Efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2005;46(Suppl 7): abstract 2350
   Google Scholar
• Valeriano J, Lane C. Efficacy and tolerability of zonisamide in generalized seizures [abstract]. Epilepsia 2001;42(Suppl 7):188
   Google Scholar
• Mullin P, Stern J, Delgado-Escueta A, Effectiveness of open-label zonisamide in juvenile myoclonic epilepsy. Epilepsia 2001;42(Suppl 7):184
   Google Scholar
• Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Levy RH, editor, Antiepileptic drugs. Philadelphia: Williams & Wilkins; 2002. p. 885-91
   Google Scholar
• Vossler D; Zonisamide PME Study Group. Multicenter, open-label, safety and efficacy study of zonisamide in patients with progressive myoclonic epilepsy. Neurology 2002;58(Suppl 3):A296-7
   Google Scholar
• Welty T, Kuzniecky R, Faught E. Outcomes of using new AED in juvenile myoclonic epilepsy. Neurology 2003;60(Suppl 1):A147
   PubMedGoogle Scholar
• Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav 2004;6:1024-6
   Google Scholar
• O'Rourke D, Flynn C, White M, Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Ir Med J 2007;4:431-3
   Google Scholar
• Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure 2004;13(Suppl 2):S34-9
   PubMedGoogle Scholar
• Montouris G, Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Epilepsia 2009;50(Suppl 8):16-20
   PubMedGoogle Scholar
• Glauser T, Pellock J. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;2:87-96
   Google Scholar
• Talwar D, Akhtar N. Clinical and electroencephalogram improvements in pediatric patients treated with zonisamide. Epilepsia 2002;43(Suppl 7):201
   PubMedGoogle Scholar
• Tanabe T, Awaya Y, Matsuishi T, Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) – a nationwide questionnaire survey in Japan. Brain Dev 2008;10:629-35
   Google Scholar
• Ohno M, Shimotsuji Y, Abe J, Zonisamide treatment of early infantile epileptic encephalopathy. Pediatr Neurol 2000;23:341-4
   PubMed Web of Science ®Google Scholar
• Yamatogi Y, Ohtahara S. Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases. Brain Dev 2002;24:13-23
   PubMed Web of Science ®Google Scholar
• Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004;2:296-8
   Google Scholar
• Suzuki Y. Zonisamide in West syndrome. Brain Dev 2001;23:658-61
   PubMed Web of Science ®Google Scholar
• Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;29:157-61
   Google Scholar
• Kishi T, Nejihashi Y, Kjiyama M, Succesful zonisamide treatment for infants with hypsarrythmia. Pediatr Neurol 2000;23:274-7
   PubMed Web of Science ®Google Scholar
• Santos C, Brotherton T. Zonisamide associated with seizure freedom in pediatric patients with Lennox-Gastaut syndrome [abstract]. Epilepsia 2003;44(Suppl 7):200
   PubMedGoogle Scholar
• Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;1-2:31-4
   Google Scholar
• You SJ, Kang HC, Kim HD, Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;4:287-90
   Google Scholar
• Sandok EK, Ruggles KH, Haessly SM, Three siblings with progressive Myoclonic epilepsy: response to adjunctive treatment with zonisamide [abstract]. Epilepsia 2001;42(Suppl 7):186
   Google Scholar
• Smith MC, Hershkowitz L, Buelow JM, Zonisamide therapy in frontal lobe or progressive Myoclonic epilepsy. Epilepsia 2002;43(Suppl 7):200
   Google Scholar
• Henry TR, Leppik IE, Gumnit RJ, Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;6:928-31
   Google Scholar
• Yoshimura I, Kaneko S, Yoshimura N, Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;3:283-7
   Google Scholar
• Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;1:31-4
   Google Scholar
• Kyllerman M, Ben Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;2:109-14
   Google Scholar
• Takahashi S, Ohinata J, Suzuki N, Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures. Epilepsy Res 2008;1:18-22
   Google Scholar
• Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008;1:19-23
   Google Scholar
• Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;2-3:75-83
   Google Scholar
• Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008;5:405-21
   Google Scholar
• Berent S, Sackellares JC, Giordani B, Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987;1:61-7
   Google Scholar
• Wilensky AJ, Friel PN, Ojemann LM, Zonisamide in epilepsy: a pilot study. Epilepsia 1985;3:212-20
   Google Scholar
• Park SP, Hwang YH, Lee HW, Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;1:102-8
   Google Scholar
• Wagner K, Metternich B, Buschmann F, Zonisamide and topiramate: an observational comparison of cognitive functions. Poster Abstract, Budapest, 28th International Epilepsy Congress; 2009
   Google Scholar
• Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 1990;2:214-17
   Google Scholar
• Sackellares JC, Donofrio PD, Wagner JG, Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985;3:206-11
   Google Scholar
• Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia 1994;2:403-5
   Google Scholar
• Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res 2006;62(Suppl 2):S17-24
   Google Scholar
• Tran TA, Leppik IE, White JR, The effect of zonisamide on weight. Epilepsia 2002;43(Suppl 7):211
   PubMedGoogle Scholar
• Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009;4:233-8
   Google Scholar
• Cho YJ, Heo K, Kim WJ, Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009;8:1910-19
   Google Scholar
• De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008;7:655-60
   Google Scholar
• Wallingford NM, Sinnayah P, Bymaster FP, Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;12:2922-33
   Google Scholar
• Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007;5:547-57
   Google Scholar
• Barbey F, Nseir G, Ferrier C, Inhibiteurs de l'anhydrase carbonique et lithiase urinaire phosphocalcique. Nephrologie 2004;169:172
   Google Scholar
• Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(Suppl 2):S18-22
   PubMedGoogle Scholar
• Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;11:1860-4
   Google Scholar
• Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009;1:3-9
   Google Scholar
• Low P, James S, Peschel T, Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res 2004;62:27-34
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006;6:1283-92
   PubMed Web of Science ®Google Scholar
• Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001;8:817-24
   Google Scholar
• Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008;2:232-5
   Google Scholar
• Shimizu A, Ikoma R, Shimulu T. Effects and side effects of zonisamide during long-term medication. Curr Ther Res 1990;47:696-706
   Google Scholar
• Kondo T, Kaneko S, Amano Y, Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;12:1242-4
   Google Scholar
• Farooq M, Moore P, Bhatt A, Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem 2008;8:968-75
   PubMed Web of Science ®Google Scholar
• Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;5:804-7
   Google Scholar